Cargando…
Can Neuropeptide S Be an Indicator for Assessing Anxiety in Psychiatric Disorders?
Neuropeptide S (NPS) is a neuropeptide primarily produced within three brainstem regions including locus coeruleus, trigeminal nerve nucleus, and lateral parabrachial nucleus. NPS is involved in the central regulation of stress, fear, and cognitive integration. NPS is a mediator of behavior, seeking...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9087177/ https://www.ncbi.nlm.nih.gov/pubmed/35558538 http://dx.doi.org/10.3389/fpubh.2022.872430 |
_version_ | 1784704146086035456 |
---|---|
author | Markiewicz-Gospodarek, Agnieszka Kuszta, Piotr Baj, Jacek Dobrowolska, Beata Markiewicz, Renata |
author_facet | Markiewicz-Gospodarek, Agnieszka Kuszta, Piotr Baj, Jacek Dobrowolska, Beata Markiewicz, Renata |
author_sort | Markiewicz-Gospodarek, Agnieszka |
collection | PubMed |
description | Neuropeptide S (NPS) is a neuropeptide primarily produced within three brainstem regions including locus coeruleus, trigeminal nerve nucleus, and lateral parabrachial nucleus. NPS is involved in the central regulation of stress, fear, and cognitive integration. NPS is a mediator of behavior, seeking food, and the proliferation of new adipocytes in the setting of obesity. So far, current research of NPS is only limited to animal models; data regarding its functions in humans is still scarce. Animal studies showed that anxiety and appetite might be suppressed by the action of NPS. The discovery of this neuromodulator peptide is effective considering its strong anxiolytic action, which has the potential to be an interesting therapeutic option in treating neuropsychiatric disorders. In this article, we aimed to analyze the pharmaceutical properties of NPS as well as its influence on several neurophysiological aspects—modulation of behavior, association with obesity, as well as its potential application in rehabilitation and treatment of psychiatric disorders. |
format | Online Article Text |
id | pubmed-9087177 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90871772022-05-11 Can Neuropeptide S Be an Indicator for Assessing Anxiety in Psychiatric Disorders? Markiewicz-Gospodarek, Agnieszka Kuszta, Piotr Baj, Jacek Dobrowolska, Beata Markiewicz, Renata Front Public Health Public Health Neuropeptide S (NPS) is a neuropeptide primarily produced within three brainstem regions including locus coeruleus, trigeminal nerve nucleus, and lateral parabrachial nucleus. NPS is involved in the central regulation of stress, fear, and cognitive integration. NPS is a mediator of behavior, seeking food, and the proliferation of new adipocytes in the setting of obesity. So far, current research of NPS is only limited to animal models; data regarding its functions in humans is still scarce. Animal studies showed that anxiety and appetite might be suppressed by the action of NPS. The discovery of this neuromodulator peptide is effective considering its strong anxiolytic action, which has the potential to be an interesting therapeutic option in treating neuropsychiatric disorders. In this article, we aimed to analyze the pharmaceutical properties of NPS as well as its influence on several neurophysiological aspects—modulation of behavior, association with obesity, as well as its potential application in rehabilitation and treatment of psychiatric disorders. Frontiers Media S.A. 2022-04-26 /pmc/articles/PMC9087177/ /pubmed/35558538 http://dx.doi.org/10.3389/fpubh.2022.872430 Text en Copyright © 2022 Markiewicz-Gospodarek, Kuszta, Baj, Dobrowolska and Markiewicz. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Public Health Markiewicz-Gospodarek, Agnieszka Kuszta, Piotr Baj, Jacek Dobrowolska, Beata Markiewicz, Renata Can Neuropeptide S Be an Indicator for Assessing Anxiety in Psychiatric Disorders? |
title | Can Neuropeptide S Be an Indicator for Assessing Anxiety in Psychiatric Disorders? |
title_full | Can Neuropeptide S Be an Indicator for Assessing Anxiety in Psychiatric Disorders? |
title_fullStr | Can Neuropeptide S Be an Indicator for Assessing Anxiety in Psychiatric Disorders? |
title_full_unstemmed | Can Neuropeptide S Be an Indicator for Assessing Anxiety in Psychiatric Disorders? |
title_short | Can Neuropeptide S Be an Indicator for Assessing Anxiety in Psychiatric Disorders? |
title_sort | can neuropeptide s be an indicator for assessing anxiety in psychiatric disorders? |
topic | Public Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9087177/ https://www.ncbi.nlm.nih.gov/pubmed/35558538 http://dx.doi.org/10.3389/fpubh.2022.872430 |
work_keys_str_mv | AT markiewiczgospodarekagnieszka canneuropeptidesbeanindicatorforassessinganxietyinpsychiatricdisorders AT kusztapiotr canneuropeptidesbeanindicatorforassessinganxietyinpsychiatricdisorders AT bajjacek canneuropeptidesbeanindicatorforassessinganxietyinpsychiatricdisorders AT dobrowolskabeata canneuropeptidesbeanindicatorforassessinganxietyinpsychiatricdisorders AT markiewiczrenata canneuropeptidesbeanindicatorforassessinganxietyinpsychiatricdisorders |